JAK Inhibitors and FDA Warnings: What Arthritis Patients Need to Know
IJMS | Free Full-Text | Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy
JAK inhibitors in 2019, synthetic review in 10 points - ScienceDirect
:max_bytes(150000):strip_icc()/jak-inhibitors-4706526-FINAL-3461d4fc6ce44f54801ef59489afa62c.png "JAK Inhibitors: Uses, Drug Options, and Side Effects")
JAK Inhibitors: Uses, Drug Options, and Side Effects
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache? | SpringerLink
Facettenreiche Januskinase-Inhibitoren
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors - ScienceDirect
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases - ScienceDirect
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM
Rituximab and JAK inhibitors Are Linked with Worse COVID-19 Outcomes in Rheumatoid Arthritis
Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED | SpringerLink
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases | SpringerLink
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases | SpringerLink
JAK inhibitors and COVID-19 | Journal for ImmunoTherapy of Cancer
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement | Annals of the Rheumatic Diseases
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors | SpringerLink
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review | SpringerLink
ACR 2020 | 'The Great Debate': JAK inhibitors vs biologics following methotrexate failure in RA | rheumatology.medicinematters.com
Frontiers | Targeting TNF-α for COVID-19: Recent Advanced and Controversies
